Clinical Trial Update: A Study of the HSP90 Inhibitor, STA-9090 in Subjects With Stage IIIB or IV Non-Small Cell Lung Cancer (NSCLC) [Phase 2]

View source ↗

Summary

Phase 2 study of the HSP90 inhibitor ganetespib (STA-9090) in stage IIIB/IV non-small cell lung cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• STA-9090 (ganetespib) (ganetespib)

Snippet

Sponsor: Synta Pharmaceuticals Corp. | Conditions: Non Small Cell Lung Cancer | Phase 2 | Status: COMPLETED